ArticleFrontiers in oncology2026
Metabolic tumor volume and total lesion glycolysis for predicting prognosis in diffuse large B-cell lymphoma: a retrospective PET/CT study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is characterized by marked clinical heterogeneity, and conventional prognostic indices provide limited individualized risk prediction. We investigated the prognostic value of baseline Methods: This retrospective study included 176 consecutive patients with histologically confirmed DLBCL who underwent baseline Results: The median age was 58 years, and 54.5% of patients were male. After a median follow-up of 26.4 months, 48 patients experienced progression; including 5 deaths without documented progression, the composite progression-free survival (PFS) endpoint comprised 53 events, and 30 patients died. The optimal cutoffs were 274.8 cm³ for MTV and 1,886.3 g for TLG. High MTV was associated with significantly inferior 2-year PFS (50.7% vs 79.9%; P<0.001) and OS (71.3% vs 92.8%; P<0.001). In multivariable analysis, high MTV remained the only significant independent predictor of PFS (HR 3.16, 95% CI 1.82-5.50; P<0.001). Incorporating MTV into the IPI improved discrimination compared with IPI alone (C-index 0.697 vs 0.567). Conclusions: In this single-center cohort, baseline MTV was a robust independent prognostic biomarker for PFS that substantially enhanced risk stratification beyond the IPI; its association with OS was exploratory given the limited number of events. Integration of volumetric PET/CT metrics into prognostic models may facilitate more individualized therapeutic decision-making. The optimism-prone, internally derived cutoff requires external validation; prospective, multicenter validation with standardized measurement protocols is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.